These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The beneficial effect of chronic lisuride administration compared with levodopa in Parkinson's disease. Rabey JM; Streifler M; Treves T; Korczyn AD Adv Neurol; 1990; 53():451-5. PubMed ID: 2122652 [No Abstract] [Full Text] [Related]
4. Long-term course in Parkinson's syndrome and cerebral polypathy (Parkinson plus). Fischer PA Adv Neurol; 1987; 45():235-8. PubMed ID: 3825695 [No Abstract] [Full Text] [Related]
5. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Parkinson Study Group CALM Cohort Investigators Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655 [TBL] [Abstract][Full Text] [Related]
6. Long-lasting drug holiday in Parkinson's disease. Bermejo F; Calandre L; Molina JA; Martinez P; De Yebenes JG Adv Neurol; 1987; 45():503-6. PubMed ID: 3103392 [No Abstract] [Full Text] [Related]
8. Longitudinal study of the motor response to levodopa in Parkinson's disease. Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259 [TBL] [Abstract][Full Text] [Related]
9. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease. Rinne UK J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601 [TBL] [Abstract][Full Text] [Related]
10. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Katzenschlager R; Head J; Schrag A; Ben-Shlomo Y; Evans A; Lees AJ; Neurology; 2008 Aug; 71(7):474-80. PubMed ID: 18579806 [TBL] [Abstract][Full Text] [Related]
11. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease. Zappia M; Montesanti R; Colao R; Branca D; Nicoletti G; Aguglia U; Quattrone A Mov Disord; 1997 Jan; 12(1):103-6. PubMed ID: 8990062 [TBL] [Abstract][Full Text] [Related]
12. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339 [TBL] [Abstract][Full Text] [Related]
13. L-deprenyl in the treatment of Parkinson's disease. Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Katona G J Neural Transm Suppl; 1983; 19():283-90. PubMed ID: 6421993 [TBL] [Abstract][Full Text] [Related]
17. Dopamine agonists as primary treatment in Parkinson's disease. Rinne UK Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394 [No Abstract] [Full Text] [Related]
18. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group. Larsen JP; Boas J Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975 [TBL] [Abstract][Full Text] [Related]
19. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Rascol O; Fabre N; Blin O; Poulik J; Sabatini U; Senard JM; Ané M; Montastruc JL; Rascol A Mov Disord; 1994 Jul; 9(4):437-40. PubMed ID: 7969211 [TBL] [Abstract][Full Text] [Related]
20. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis. Merello M; Nouzeilles MI; Arce GP; Leiguarda R Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]